{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T17:09:58Z","timestamp":1781284198926,"version":"3.54.1"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.vph.2023.107223","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T13:56:51Z","timestamp":1694181411000},"page":"107223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Antineoplastic drugs inducing cardiac and vascular toxicity \u2013 An update"],"prefix":"10.1016","volume":"153","author":[{"given":"Serena","family":"Barachini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Ghelardoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n V.","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radwa A.","family":"Mehanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Magdalena","family":"Montt-Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Ferdinandy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalinda","family":"Madonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.vph.2023.107223_bb0005","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/eurheartj\/ehy365","article-title":"Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications","volume":"40","author":"Ferdinandy","year":"2019","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.vph.2023.107223_bb0010","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/ejhf.1985","article-title":"The cancer patient and cardiology","volume":"22","author":"Zamorano","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"284","key":"10.1016\/j.vph.2023.107223_bb0015","first-page":"124","article-title":"Reactive oxygen species - sources, functions, oxidative damage","volume":"48","author":"Jakubczyk","year":"2020","journal-title":"Pol. Merkur. Lekarski"},{"issue":"4","key":"10.1016\/j.vph.2023.107223_bb0020","first-page":"350","article-title":"Free radicals and activated oxygen","volume":"5","author":"Famaey","year":"1982","journal-title":"Eur. J. Rheumatol. Inflamm."},{"issue":"6","key":"10.1016\/j.vph.2023.107223_bb0025","first-page":"L1005","article-title":"Reactive oxygen species in cell signaling","volume":"279","author":"Thannickal","year":"2000","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"issue":"9","key":"10.1016\/j.vph.2023.107223_bb0030","doi-asserted-by":"crossref","first-page":"H1453","DOI":"10.1152\/ajpheart.00554.2015","article-title":"Drug-induced mitochondrial dysfunction and cardiotoxicity","volume":"309","author":"Varga","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.vph.2023.107223_bb0035","unstructured":"StatPearls. 2023."},{"issue":"2","key":"10.1016\/j.vph.2023.107223_bb0040","first-page":"455","article-title":"Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis","volume":"59","author":"Melincovici","year":"2018","journal-title":"Romanian J. Morphol. Embryol."},{"key":"10.1016\/j.vph.2023.107223_bb0045","article-title":"The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF","volume":"949(175586","author":"Ghalehbandi","year":"2023","journal-title":"Eur. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.vph.2023.107223_bb0050","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1248\/bpb.34.1785","article-title":"Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy","volume":"34","author":"Takahashi","year":"2011","journal-title":"Biol. Pharm. Bull."},{"issue":"2","key":"10.1016\/j.vph.2023.107223_bb0055","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1021\/acs.molpharmaceut.2c00792","article-title":"Recent advances in boosting EGFR tyrosine kinase inhibitors-based Cancer therapy","volume":"20","author":"Pan","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.vph.2023.107223_bb0060","doi-asserted-by":"crossref","first-page":"114491","DOI":"10.1016\/j.biopha.2023.114491","article-title":"New insights about the PDGF\/PDGFR signaling pathway as a promising target to develop cancer therapeutic strategies","volume":"161","author":"Pandey","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.vph.2023.107223_bb0065","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd2792","article-title":"The FGF family: biology, pathophysiology and therapy","volume":"8","author":"Beenken","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.vph.2023.107223_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15384101.2022.2108117","article-title":"Cell cycle control by the insulin-like growth factor signal: at the crossroad between cell growth and mitotic regulation","volume":"22","author":"Scalia","year":"2023","journal-title":"Cell Cycle"},{"issue":"5","key":"10.1016\/j.vph.2023.107223_bb0075","doi-asserted-by":"crossref","first-page":"352","DOI":"10.5603\/AIT.a2016.0051","article-title":"Coagulopathy in sepsis - a new look at an old problem","volume":"48","author":"Lipinska-Gediga","year":"2016","journal-title":"Anaesthesiol Intens Ther"},{"issue":"8","key":"10.1016\/j.vph.2023.107223_bb0080","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.it.2018.04.010","article-title":"Immune factors in deep vein thrombosis initiation","volume":"39","author":"Budnik","year":"2018","journal-title":"Trends Immunol."},{"key":"10.1016\/j.vph.2023.107223_bb0085","article-title":"The role of inflammation in venous thromboembolism","volume":"6(142","author":"Branchford","year":"2018","journal-title":"Front. Pediatr."},{"issue":"1","key":"10.1016\/j.vph.2023.107223_bb0090","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3324\/haematol.11677","article-title":"Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor","volume":"93","author":"Bockmeyer","year":"2008","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.vph.2023.107223_bb0095","doi-asserted-by":"crossref","first-page":"H1091","DOI":"10.1152\/ajpheart.00290.2018","article-title":"Doxorubicin triggers splenic contraction and irreversible dysregulation of COX and LOX that alters the inflammation-resolution program in the myocardium","volume":"315","author":"Jadapalli","year":"2018","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"11","key":"10.1016\/j.vph.2023.107223_bb0100","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3390\/toxins2112490","article-title":"Mechanisms of cisplatin nephrotoxicity","volume":"2","author":"Miller","year":"2010","journal-title":"Toxins (Basel)"},{"issue":"8","key":"10.1016\/j.vph.2023.107223_bb0105","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1021\/acs.chemrestox.9b00204","article-title":"Advances in toxicological research of the anticancer drug cisplatin","volume":"32","author":"Qi","year":"2019","journal-title":"Chem. Res. Toxicol."},{"issue":"5","key":"10.1016\/j.vph.2023.107223_bb0110","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ctrv.2011.09.002","article-title":"Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications","volume":"38","author":"Soultati","year":"2012","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"10.1016\/j.vph.2023.107223_bb0115","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11886-023-01845-2","article-title":"Cardiovascular toxicities associated with tyrosine kinase inhibitors","volume":"25","author":"Sayegh","year":"2023","journal-title":"Curr. Cardiol. Rep."},{"issue":"6","key":"10.1016\/j.vph.2023.107223_bb0120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11912-016-0514-0","article-title":"Tyrosine kinase inhibitors and vascular toxicity: impetus for a classification system?","volume":"18","author":"Herrmann","year":"2016","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.vph.2023.107223_bb0125","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.semcdb.2019.05.006","article-title":"Metabolic and non-metabolic pathways that control cancer resistance to anthracyclines","volume":"98","author":"Capel\u00f4a","year":"2020","journal-title":"Semin. Cell Dev. Biol."},{"issue":"18","key":"10.1016\/j.vph.2023.107223_bb0130","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1089\/ars.2016.6930","article-title":"From molecular mechanisms to clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: a translational overview","volume":"30","author":"Tocchetti","year":"2019","journal-title":"Antioxid. Redox Signal."},{"issue":"3","key":"10.1016\/j.vph.2023.107223_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2019.06.007","article-title":"Autophagy and cancer therapy cardiotoxicity: from molecular mechanisms to therapeutic opportunities","volume":"1867","author":"Li","year":"2020","journal-title":"Biochim. Biophys. Acta, Mol. Cell Res."},{"issue":"3B","key":"10.1016\/j.vph.2023.107223_bb0140","first-page":"2193","article-title":"Relationship between topoisomerase II-DNA cleavable complexes, apoptosis and cytotoxic activity of anthracyclines in human cervix carcinoma cells","volume":"25","author":"Gruber","year":"2005","journal-title":"Anticancer Res."},{"issue":"18","key":"10.1016\/j.vph.2023.107223_bb0145","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","article-title":"Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane","volume":"67","author":"Lyu","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.vph.2023.107223_bb0150","doi-asserted-by":"crossref","first-page":"102120","DOI":"10.1016\/j.redox.2021.102120","article-title":"Irisin ameliorates doxorubicin-induced cardiac perivascular fibrosis through inhibiting endothelial-to-mesenchymal transition by regulating ROS accumulation and autophagy disorder in endothelial cells","volume":"46","author":"Pan","year":"2021","journal-title":"Redox Biol."},{"key":"10.1016\/j.vph.2023.107223_bb0155","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.mito.2016.07.005","article-title":"Cardiac cytochrome c and cardiolipin depletion during anthracycline-induced chronic depression of mitochondrial function","volume":"30","author":"Pereira","year":"2016","journal-title":"Mitochondrion"},{"key":"10.1016\/j.vph.2023.107223_bb0160","doi-asserted-by":"crossref","first-page":"114733","DOI":"10.1016\/j.biopha.2023.114733","article-title":"Integration of transcriptomics, metabolomics, and lipidomics reveals the mechanisms of doxorubicin-induced inflammatory responses and myocardial dysfunction in mice","volume":"162","author":"Tan","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.vph.2023.107223_bb0165","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJMra044389","article-title":"Tyrosine kinases as targets for cancer therapy","volume":"353","author":"Krause","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.vph.2023.107223_bb0170","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.hrthm.2019.04.008","article-title":"Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium","volume":"16","author":"Jiang","year":"2019","journal-title":"Heart Rhythm."},{"issue":"25","key":"10.1016\/j.vph.2023.107223_bb0175","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","article-title":"Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase","volume":"142","author":"Xiao","year":"2020","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.vph.2023.107223_bb0180","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.vph.2023.107223_bb0185","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1172\/JCI86249","article-title":"Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension","volume":"126","author":"Guignabert","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.vph.2023.107223_bb0190","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12916-023-02838-2","article-title":"Three tyrosine kinase inhibitors cause cardiotoxicity by inducing endoplasmic reticulum stress and inflammation in cardiomyocytes","volume":"21","author":"Wang","year":"2023","journal-title":"BMC Med."},{"issue":"4","key":"10.1016\/j.vph.2023.107223_bb0195","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000073","article-title":"Twenty years of anti-HER2 therapy-associated cardiotoxicity","volume":"1","author":"Pond\u00e9","year":"2016","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.vph.2023.107223_bb0200","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2174\/1568009618666171129222159","article-title":"Toxicology of Trastuzumab: An insight into mechanisms of cardiotoxicity","volume":"19","author":"An","year":"2019","journal-title":"Curr. Cancer Drug Targets"},{"issue":"6","key":"10.1016\/j.vph.2023.107223_bb0205","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cardfail.2016.04.008","article-title":"Models of heart failure based on the cardiotoxicity of anticancer drugs","volume":"22","author":"Mercurio","year":"2016","journal-title":"J. Card. Fail."},{"issue":"3","key":"10.1016\/j.vph.2023.107223_bb0210","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10557-021-07181-3","article-title":"The molecular mechanisms of cardiotoxicity induced by HER2, VEGF, and tyrosine kinase inhibitors: an updated review","volume":"36","author":"Wu","year":"2022","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.vph.2023.107223_bb0215","article-title":"Recent advances and future perspectives of noncompetitive proteasome inhibitors","volume":"135(106507","author":"Zeng","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"3","key":"10.1016\/j.vph.2023.107223_bb0220","article-title":"Cardiotoxicity of non-anthracycline Cancer chemotherapy agents","volume":"9","author":"Briasoulis","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"issue":"5","key":"10.1016\/j.vph.2023.107223_bb0225","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/ehjci\/jeac168","article-title":"Cardiac mechanics in response to proteasome inhibition: a prospective study","volume":"24","author":"Makris","year":"2023","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"issue":"4","key":"10.1016\/j.vph.2023.107223_bb0230","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1161\/CIRCRESAHA.119.316007","article-title":"The Calcineurin-TFEB-p62 pathway mediates the activation of cardiac macroautophagy by proteasomal malfunction","volume":"127","author":"Pan","year":"2020","journal-title":"Circ. Res."},{"issue":"3\u20134","key":"10.1016\/j.vph.2023.107223_bb0235","first-page":"121","article-title":"Molecular Cardiotoxic effects of proteasome inhibitors carfilzomib and Ixazomib and their combination with dexamethasone involve mitochondrial dysregulation","volume":"23","author":"Jannuzzi","year":"2023","journal-title":"Cardiovasc. Toxicol."},{"issue":"11","key":"10.1016\/j.vph.2023.107223_bb0240","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13715","article-title":"Autophagy activation can partially rescue proteasome dysfunction-mediated cardiac toxicity","volume":"21","author":"Papanagnou","year":"2022","journal-title":"Aging Cell"},{"issue":"13","key":"10.1016\/j.vph.2023.107223_bb0245","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.115.018347","article-title":"Vascular toxicities of cancer therapies: the old and the new--an evolving avenue","volume":"133","author":"Herrmann","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2023.107223_bb0250","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.tox.2016.10.001","article-title":"An integrative view of cisplatin-induced renal and cardiac toxicities: molecular mechanisms, current treatment challenges and potential protective measures","volume":"371","author":"Dugbartey","year":"2016","journal-title":"Toxicology"},{"issue":"24","key":"10.1016\/j.vph.2023.107223_bb0255","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1136\/heartjnl-2018-313726","article-title":"Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors","volume":"104","author":"Dobbin","year":"2018","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.vph.2023.107223_bb0260","article-title":"Cardiovascular toxicity induced by vascular endothelial growth factor inhibitors","volume":"13","author":"Mihalcea","year":"2023","journal-title":"Life (Basel)"},{"issue":"19","key":"10.1016\/j.vph.2023.107223_bb0265","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10194426","article-title":"Cardiotoxicity of Fluoropyrimidines: epidemiology, mechanisms, diagnosis, and management","volume":"10","author":"Jurczyk","year":"2021","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.vph.2023.107223_bb0270","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11886-021-01441-2","article-title":"5-FU cardiotoxicity: vasospasm, myocarditis, and sudden death","volume":"23","author":"More","year":"2021","journal-title":"Curr. Cardiol. Rep."},{"issue":"4","key":"10.1016\/j.vph.2023.107223_bb0275","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11864-020-0719-1","article-title":"Cardiotoxicities of 5-fluorouracil and other Fluoropyrimidines","volume":"21","author":"Shiga","year":"2020","journal-title":"Curr. Treat. Options in Oncol."},{"issue":"1","key":"10.1016\/j.vph.2023.107223_bb0280","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/00000658-198807000-00007","article-title":"Construction of an ileal reservoir in patients with a previous straight endorectal ileal pull-through","volume":"208","author":"Fonkalsrud","year":"1988","journal-title":"Ann. Surg."},{"issue":"1","key":"10.1016\/j.vph.2023.107223_bb0285","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.vph.2023.107223_bb0290","doi-asserted-by":"crossref","first-page":"989431","DOI":"10.3389\/fphar.2022.989431","article-title":"The role of immune checkpoints in cardiovascular disease","volume":"13","author":"Yousif","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.vph.2023.107223_bb0295","doi-asserted-by":"crossref","first-page":"516450","DOI":"10.1155\/2015\/516450","article-title":"Cancer and cardiovascular disease: the complex labyrinth","volume":"2015","author":"Dent","year":"2015","journal-title":"J. Oncol."},{"issue":"4","key":"10.1016\/j.vph.2023.107223_bb0300","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3322\/caac.21341","article-title":"Cardiotoxicity of anticancer treatments: epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.vph.2023.107223_bb0305","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev-med-041316-090622","article-title":"Common cardiovascular complications of cancer therapy: epidemiology, risk prediction, and prevention","volume":"69","author":"Narayan","year":"2018","journal-title":"Annu. Rev. Med."},{"issue":"4","key":"10.1016\/j.vph.2023.107223_bb0310","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1161\/HYPERTENSIONAHA.117.10490","article-title":"VEGFR (vascular endothelial growth factor receptor) inhibition induces cardiovascular damage via redox-sensitive processes","volume":"71","author":"Neves","year":"2018","journal-title":"Hypertension"},{"issue":"11","key":"10.1016\/j.vph.2023.107223_bb0315","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1038\/bjc.2012.152","volume":"106","author":"Dewdney","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"187","key":"10.1016\/j.vph.2023.107223_bb0320","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005066","article-title":"Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity","volume":"5","author":"Chintalgattu","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.vph.2023.107223_bb0325","doi-asserted-by":"crossref","first-page":"694711","DOI":"10.3389\/fcvm.2021.694711","article-title":"Updates on anticancer therapy-mediated vascular toxicity and new horizons in therapeutic strategies","volume":"8","author":"Hsu","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"Suppl. 1","key":"10.1016\/j.vph.2023.107223_bb0330","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0049-3848(20)30391-1","article-title":"An overview of thrombotic complications of old and new anticancer drugs","volume":"191","author":"Levi","year":"2020","journal-title":"Thromb. Res."},{"issue":"6","key":"10.1016\/j.vph.2023.107223_bb0335","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s00380-011-0222-5","article-title":"Primary percutaneous coronary intervention and intravascular ultrasound imaging for coronary thrombosis after cisplatin-based chemotherapy","volume":"27","author":"Ito","year":"2012","journal-title":"Heart Vessel."},{"issue":"9","key":"10.1016\/j.vph.2023.107223_bb0340","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jcmg.2010.06.012","article-title":"Visualizing the vascular glue \u201cshearing\u201d the barriers to atherosclerotic plaque imaging","volume":"3","author":"Libby","year":"2010","journal-title":"JACC Cardiovasc. Imaging"},{"issue":"8","key":"10.1016\/j.vph.2023.107223_bb0345","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41569-020-0347-2","article-title":"Vascular toxic effects of cancer therapies","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"issue":"9","key":"10.1016\/j.vph.2023.107223_bb0350","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1161\/01.ATV.0000233387.90257.9b","article-title":"Angiogenesis in atherogenesis","volume":"26","author":"Herrmann","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.vph.2023.107223_bb0355","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s00059-011-3444-5","article-title":"Sorafenib-associated multivessel coronary artery vasospasm","volume":"36","author":"Naib","year":"2011","journal-title":"Herz"},{"issue":"4","key":"10.1016\/j.vph.2023.107223_bb0360","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/14779072.2022.2063840","article-title":"Acute coronary syndrome in patients with cancer","volume":"20","author":"Shobayo","year":"2022","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"issue":"5","key":"10.1016\/j.vph.2023.107223_bb0365","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.vph.2023.107223_bb0370","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1021\/acs.chemrestox.9b00387","article-title":"Cardiovascular toxicity induced by kinase inhibitors: mechanisms and preclinical approaches","volume":"33","author":"Lamore","year":"2020","journal-title":"Chem. Res. Toxicol."},{"issue":"8","key":"10.1016\/j.vph.2023.107223_bb0375","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkel\u00e4","year":"2006","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.vph.2023.107223_bb0380","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","article-title":"Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention","volume":"104","author":"Henriksen","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.vph.2023.107223_bb0385","first-page":"127(4","article-title":"Doxorubicin targets multiple players: a new view of an old problem","author":"Cappetta","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.vph.2023.107223_bb0390","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pharmthera.2019.06.001","article-title":"Vascular disrupting agents in cancer treatment: cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics","volume":"202","author":"Gill","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"17","key":"10.1016\/j.vph.2023.107223_bb0395","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.vph.2023.107223_bb0400","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"7937","key":"10.1016\/j.vph.2023.107223_bb0405","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","article-title":"T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod","year":"2022","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.vph.2023.107223_bb0410","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.vph.2023.107223_bb0415","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/CIRCULATIONAHA.120.051753","article-title":"By releasing the brakes with immunotherapy, are we accelerating atherosclerosis?","volume":"142","author":"Kondapalli","year":"2020","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.vph.2023.107223_bb0420","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.vph.2023.107223_bb0425","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/bph.15984","article-title":"Characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals interleukin-17A as a driver of cardiac dysfunction after anti-PD-1 treatment","volume":"180","author":"Gergely","year":"2023","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2023.107223_bb0430","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2021.09.010","article-title":"Immune checkpoint inhibitors for cancer and venous thromboembolic events","volume":"158","author":"Gong","year":"2021","journal-title":"Eur. J. Cancer"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189123000836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189123000836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T07:02:15Z","timestamp":1724655735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189123000836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":86,"alternative-id":["S1537189123000836"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2023.107223","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antineoplastic drugs inducing cardiac and vascular toxicity \u2013 An update","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2023.107223","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107223"}}